1. Home
  2. CYPH vs DRIO Comparison

CYPH vs DRIO Comparison

Compare CYPH & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CYPH

Cypherpunk Technologies Inc.

N/A

Current Price

$0.99

Market Cap

73.4M

Sector

Health Care

ML Signal

N/A

Logo DarioHealth Corp.

DRIO

DarioHealth Corp.

N/A

Current Price

$7.23

Market Cap

61.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CYPH
DRIO
Founded
2011
2011
Country
United States
United States
Employees
6
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.4M
61.8M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
CYPH
DRIO
Price
$0.99
$7.23
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$35.00
AVG Volume (30 Days)
2.5M
15.2K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1559.02
EPS
N/A
10.12
Revenue
N/A
$7,394,000.00
Revenue This Year
N/A
$20.27
Revenue Next Year
N/A
$47.58
P/E Ratio
N/A
$0.74
Revenue Growth
N/A
43.02
52 Week Low
$0.50
$0.38
52 Week High
$3.70
$17.74

Technical Indicators

Market Signals
Indicator
CYPH
DRIO
Relative Strength Index (RSI) 60.96 53.55
Support Level $0.94 $7.37
Resistance Level $1.01 $9.46
Average True Range (ATR) 0.10 0.35
MACD 0.00 0.12
Stochastic Oscillator 66.66 82.87

Price Performance

Historical Comparison
CYPH
DRIO

About CYPH Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.

About DRIO DarioHealth Corp.

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

Share on Social Networks: